Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Other Operating Expenses (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Other Operating Expenses for 5 consecutive years, with $32.1 million as the latest value for Q2 2020.

  • Quarterly Other Operating Expenses changed N/A to $32.1 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $31.2 million through Dec 2020, up 240.79% year-over-year, with the annual reading at $600000.0 for FY2025, 25.26% up from the prior year.
  • Other Operating Expenses for Q2 2020 was $32.1 million at Forte Biosciences, up from -$885000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $32.1 million in Q2 2020, with the low at -$885000.0 in Q1 2020.
  • Average Other Operating Expenses over 5 years is $6.7 million, with a median of $0.0 recorded in 2016.
  • The sharpest move saw Other Operating Expenses crashed 200.0% in 2017, then skyrocketed 914800.0% in 2019.
  • Over 5 years, Other Operating Expenses stood at $1000.0 in 2016, then plummeted by 200.0% to -$1000.0 in 2017, then changed by 0.0% to -$1000.0 in 2018, then surged by 914800.0% to $9.1 million in 2019, then soared by 250.46% to $32.1 million in 2020.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $32.1 million, -$885000.0, and $9.1 million for Q2 2020, Q1 2020, and Q4 2019 respectively.